MX2009005164A - Metodo para preparar montelukast e intermediarios usados en el mismo. - Google Patents

Metodo para preparar montelukast e intermediarios usados en el mismo.

Info

Publication number
MX2009005164A
MX2009005164A MX2009005164A MX2009005164A MX2009005164A MX 2009005164 A MX2009005164 A MX 2009005164A MX 2009005164 A MX2009005164 A MX 2009005164A MX 2009005164 A MX2009005164 A MX 2009005164A MX 2009005164 A MX2009005164 A MX 2009005164A
Authority
MX
Mexico
Prior art keywords
intermediates used
montelukast
preparing montelukast
preparing
prepared
Prior art date
Application number
MX2009005164A
Other languages
English (en)
Inventor
Young-Kil Chang
Gwan Sun Lee
Jaeheon Lee
Jaeho Yoo
Chul Hyun Park
Eun-Ju Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2009005164A publication Critical patent/MX2009005164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se relaciona con un método para preparar montelukast, un inhibidor contra leucotrienos, y un intermediario usado en el mismo. De conformidad con el método inventivo, montelukast de pureza elevado o su sal de sodio se pueden preparar en un rendimiento elevado.
MX2009005164A 2006-12-14 2007-12-11 Metodo para preparar montelukast e intermediarios usados en el mismo. MX2009005164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060127942A KR100774088B1 (ko) 2006-12-14 2006-12-14 몬테루카스트의 제조방법 및 이에 사용되는 중간체
PCT/KR2007/006424 WO2008072872A1 (en) 2006-12-14 2007-12-11 Method of preparing montelukast and intermediates used therein

Publications (1)

Publication Number Publication Date
MX2009005164A true MX2009005164A (es) 2009-05-27

Family

ID=39061099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005164A MX2009005164A (es) 2006-12-14 2007-12-11 Metodo para preparar montelukast e intermediarios usados en el mismo.

Country Status (12)

Country Link
US (1) US8217174B2 (es)
EP (1) EP2114889B1 (es)
JP (1) JP5017696B2 (es)
KR (1) KR100774088B1 (es)
CN (1) CN101558042B (es)
AR (1) AR064327A1 (es)
CA (1) CA2673098C (es)
ES (1) ES2446016T3 (es)
MX (1) MX2009005164A (es)
RU (1) RU2408583C1 (es)
TW (1) TWI382017B (es)
WO (1) WO2008072872A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
WO2009138993A1 (en) * 2008-05-13 2009-11-19 Macleods Pharmaceuticals Limited A process for preparation of montelukast sodium salt
KR101123292B1 (ko) 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
KR100893756B1 (ko) * 2009-01-14 2009-04-22 주식회사 메디켐코리아 몬테루카스트의 효율적 제조방법
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
CN104293850B (zh) * 2014-08-12 2017-08-04 江苏恒盛药业有限公司 孟鲁司特钠的制备工艺及其中间产物
CN106831863B (zh) * 2017-01-20 2018-09-21 山东百诺医药股份有限公司 孟鲁司特钠中间体及其制备方法和应用
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
CN111892535B (zh) * 2020-08-27 2023-04-11 鲁南制药集团股份有限公司 一种孟鲁司特钠的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
ID23656A (id) * 1997-03-13 2000-05-11 Merck & Co Inc Antagonis-antagonis kinolin leukotriena
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
MXPA06012220A (es) * 2004-04-21 2007-07-18 Teva Pharma Procesos para preparar sodio de montelukast.
WO2006008751A2 (en) 2004-07-19 2006-01-26 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
US20080214822A1 (en) 2004-11-30 2008-09-04 Medichem, S.A. Process For the Preparation of a Leukotriene Antagonist

Also Published As

Publication number Publication date
EP2114889A4 (en) 2010-12-22
JP2010512309A (ja) 2010-04-22
WO2008072872A1 (en) 2008-06-19
EP2114889A1 (en) 2009-11-11
US20100099876A1 (en) 2010-04-22
TW200831466A (en) 2008-08-01
US8217174B2 (en) 2012-07-10
CN101558042A (zh) 2009-10-14
KR100774088B1 (ko) 2007-11-06
TWI382017B (zh) 2013-01-11
CA2673098C (en) 2011-10-04
CN101558042B (zh) 2011-05-18
EP2114889B1 (en) 2014-01-22
JP5017696B2 (ja) 2012-09-05
ES2446016T3 (es) 2014-03-06
CA2673098A1 (en) 2008-06-19
RU2408583C1 (ru) 2011-01-10
AR064327A1 (es) 2009-03-25

Similar Documents

Publication Publication Date Title
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
MX347257B (es) Solido de gamma-carbolinas fusionadas con heterociclos substituidos.
PH12013500760B1 (en) Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same
MX340064B (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
WO2007093627A3 (de) Biozide zusammensetzung
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
WO2007095116A3 (en) Glass compositions for protecting glass and methods of making and using thereof
MX2012007717A (es) Cepas y metodo para la produccion de metionina.
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
CA2905610C (en) Hyaluronic acid derivatives
GEP20135800B (en) Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation
MY158910A (en) Surface modified silicic acid semi-gels
MY155330A (en) Methods for salt production
UA94837C2 (ru) Способ синтеза (7-метокси-1-нафтил)ацетонитрила и применение в синтезе агомелатина
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
MX2011008275A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MX2011012233A (es) Soluciones de retinoide topicas.
MX2012003888A (es) Semigeles de acido silicico de superficie modificada.
MD307Z (ro) Inhibitor de coroziune a oţelului în apă

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status